Retinoic acid elicits a coordinated expression of gut homing markers on T lymphocytes of Zambian men receiving oral Vivotif, but not Rotarix, Dukoral or OPVERO vaccines by Mwanza-Lisulo, M et al.
Vaccine 36 (2018) 4134–4141Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vaccineRetinoic acid elicits a coordinated expression of gut homing markers on
T lymphocytes of Zambian men receiving oral Vivotif, but not Rotarix,
Dukoral or OPVERO vaccineshttps://doi.org/10.1016/j.vaccine.2018.04.083
0264-410X/ 2018 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Abbreviations: ATRA, all-trans retinoic acid; RA, retinoic acid; CCR9, chemokine
receptor 9; WGLF, whole gut lavage fluid.
⇑ Corresponding author at: TROPGAN Office, Department of Internal Medicine,
University of Zambia School of Medicine, University Teaching Hospital, Nationalist
Road, Lusaka, Zambia.
E-mail address: mpalamwanza123@gmail.com (M. Mwanza-Lisulo).Mpala Mwanza-Lisulo a,⇑, Mumba S. Chomba a, Mubanga Chama a,b, Ellen C. Besa a, Evelyn Funjika a,b,
Kanekwa Zyambo a, Rose Banda a, Mercy Imikendu a, Sandie Sianongo a, Robert E.W. Hancock c, Amy Lee c,
Roma Chilengi d, Andy J. Stagg e, Boniface Namangala f, Paul M. Kelly a,e
a Tropical Gastroenterology & Nutrition Group, Department of Medicine, School of Medicine, University of Zambia, Lusaka, Zambia
bDepartment of Chemistry, University of Zambia, Lusaka, Zambia
cUniversity of British Columbia, Vancouver, Canada
dCentre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia
eBlizard Institute, Barts & The London School of Medicine, Queen Mary University of London, London, UK
f Institute of Distance Education, University of Zambia, Lusaka, Zambia
a r t i c l e i n f o a b s t r a c tArticle history:
Received 17 January 2018
Received in revised form 29 March 2018
Accepted 30 April 2018






VaccinesAll-trans retinoic acid (ATRA) up-regulates, in laboratory animals, the expression of the gut homing mark-
ers a4b7 integrin and CCR9 on lymphocytes, increasing their gut tropism. Here, we show that, in healthy
adult volunteers, ATRA induced an increase of these gut homing markers on T cells in vivo in a time
dependent manner. The coordinated increase of a4b7 and CCR9 by ATRA was seen in 57% (12/21) of vol-
unteers and only when given together with an oral Vivotif vaccine. When this coordinated response to
ATRA and Vivotif vaccine was present, it was strongly correlated with the gut immunoglobulin A (IgA)
specific response to vaccine LPS (q = 0.82; P = 0.02). Using RNA-Seq analysis of whole blood transcription,
patients receiving ATRA and Vivotif in conjunction showed transcriptomic changes in immune-related
pathways, particularly including interferon a/b signaling pathway, membrane-ECM interactions and
immune hubs. These results suggest that exogenous ATRA can be used to manipulate responses to a sub-
class of oral vaccines, so far limited to a live attenuated Vivotif vaccine.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
There is strong evidence of diminished immunogenicity and
efficacy of oral vaccines in developing country populations [1].
For example, oral rotavirus vaccine affords excellent (80–90%) pro-
tection against severe rotavirus diarrhea in industrialized and mid-
dle income countries but has been less efficacious when tested in
infants in the developing world [2,3]. The trivalent oral polio vac-
cine (OPVERO) has also been found to be less effective in children
in the developing world [4] with estimated efficacies of around 21%
in India compared to 50% in the United States [5]. In view of this,there is an urgent need to identify ways to improve immune
responses of these oral vaccines in the settings where they are
most needed.
Vitamin A supplementation significantly reduces mortality
from diarrheal infections as evidenced by results of several studies
[6–9]. The mechanism of protection however is unclear [6,9].
Vitamin A is oxidized to four isoforms of retinoic acid (RA);
these include all-trans RA (ATRA), 9-cis RA, 13-cis RA, and 11-cis
RA. The RAs have important immunological functions especially
on intestinal defense and mucosal immune responses.
Selective migration of the effector T cells to the gut requires the
expression of a4b7-integrin and the chemokine receptor, CCR9.
Integrin a4b7 is the homing receptor for the small and large intes-
tine, whereas CCR9 is the small intestine-specific homing receptor
[10]. Several studies have shown that RA is a key mediator of T cell
homing to the gut [11–13]. Iwata and colleagues [11] demon-
strated that CD4+ T cells activated in vitro in the presence of ATRA
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integrin and CCR9. Hammerschmidt and colleagues [12] demon-
strated that RA-assisted subcutaneous immunization resulted in
pronounced localization of antigen-specific plasma cells in the
small intestine and a robust immunoglobulin A (IgA) response in
serum and intestinal washes. In recent preliminary work [14], we
found that ATRA could enhance gut IgA responses to Vivotif
typhoid vaccine in intestinal washes. Collectively these observa-
tions suggest that RA-assisted immunization generates intestinal
immunity and confers the benefits of mucosal protection.
Retinoic acid has been known to affect expression of the poly-
meric immunoglobulin receptor (pIgR) [15] which transports poly-
meric immunoglobulin A (pIgA) into external secretions as
secretory IgA (S-IgA). This suggests that vitamin A might be
required for the proper regulation of IgA transport in response to
mucosal infection, which would be a desirable characteristic of
an orally-active adjuvant [16,17].
The present study investigated whether the ATRA adjuvanticity
seen with Vivotif vaccine in African men could be generalized to
other oral vaccines. We asked if ATRA given alongside oral vaccines
could improve the immune response by enhancing expression of




We recruited 94 adult male volunteers aged between 18 and 60
years from a high- density township in Lusaka, Zambia, as previ-
ously described [14]. A 3-stage consent process was used [20,21].
Nutritional assessment and HIV testing was done. Details in Sup-
plementary material methods.
2.2. Ethical Approval
Approval for the study was obtained from the Biomedical
Research Ethics Committee of the University of Zambia (references
012-06-12 and 013-01-14).
2.3. Vaccine administration and sample collection
Recruited volunteers (n = 94) were randomized to receive one
of four oral vaccines: Vivotif (Crucell, Switzerland) [22,23], Dukoral
(SBLVaccines), Rotarix (GSK), and OPVERO (Sanofi Pasteur). Each
vaccine was given with or without ATRA on day 1. ATRA was
administered as 10 mg daily for 8 days and 1 h before vaccination.
Vivotif was given on days 1, 3 and 5 while Dukoral, Rotarix and
OPVERO were administered as single doses. Whole gut lavage fluid
was collected as previously described [14,25] on days 0 and 14 (see
supplementary material methods). Blood was also collected at the
same time-points for the serum antibody assays.
2.4. Detection of Vivotif and Dukoral-specific IgA and IgG in serum and
gut lavages
Vivotif and Dukoral LPS antigen preparations were made using
a modified phenol extraction technique as previously described
[14,22]. Analysis of vaccine specific antibodies in serum and gut
lavages was performed as described previously [14].
2.5. Detection of Rotarix-specific IgA and IgG in serum and gut lavages
Analysis of IgA and IgG antibody responses was done using
ELISA (see supplementary material).2.6. Detection of OPVERO-specific IgA and IgG in serum
Analysis of OPVERO-specific antibodies in serum was per-
formed by neutralization.
2.7. Analysis of effects of ATRA on polymeric Ig receptor (pIgR)
Biopsies (<20 mg of tissue) were collected from the jejunum of
13 participants and analyzed for the effect of ATRA on expression
of pIgR (for details refer to Supplementary material methods).
2.8. Analysis of baseline serum retinol concentrations
Retinol in serum was assayed by high performance liquid chro-
matography (HPLC) modified version [26].
2.9. Transcriptome analysis of effects of ATRA during vaccination
Blood samples were collected from 8 male individuals given
both ATRA and Vivotif on day 0 (baseline) and day 8. Each sample
comprised 2.5 ml of blood directly drawn into a PAXgene blood
RNA tube (Qiagen), inverted 10 times, then kept at room tempera-
ture for 2 h before being stored at 80 C until RNA extraction (see
Supplementary material methods for more details).
2.10. Statistical analyses
All graphical and statistical tests were performed using Graph-
Pad Prism 6.0 (La Jolla, CA) and STATA 12 (Stata Corp, College Sta-
tion, TX, USA). Statistical comparisons were done using
nonparametric tests (Mann-Whitney, Kruskal-Wallis and Spear-
man’s rank correlation coefficient). Gut lavage responses are
expressed as change in log titer values; P values <0.05 were
assumed significant.
3. Results
In total, 94 participants were randomized to receive one of 4
vaccines and participant demographics are described in Table 1.
The HIV prevalence in this study cohort was 21% with average
age being 29 years and nutritional status comparable in each
group. We report combined data for HIV infected and non-
infected, as we found HIV infection had no effect on the intestinal
IgA response to Vivotif (Supplementary Fig. 1).
3.1. ATRA increased gut IgA directed at Vivotif LPS, but not other
vaccine antigens
Antibody titers to Vivotif, Dukoral and Rotarix were measured
as changes in log titers in response to vaccination with or without
daily administration of 10 mg ATRA for 8 days. Antibody titers in
whole gut fluid against Vivotif LPS antigen were significantly
increased (Fig. 1A) in the group that received Vivotif vaccine as
well as ATRA, consistent with our previous findings [14]. There
was no significant change in mucosal responses to Rotarix antigens
or Dukoral (whether LPS or CTB) antigens in gut lavage samples
(Fig. 1B-D). Antibody titers in serum showed no significant change
in any of the vaccine groups (Supplementary Fig. 2). This increase
in specific IgA was not a consequence of increased pIgR expression
in intestinal biopsies (Supplementary Fig. 3).
3.2. Effect of ATRA was vaccine and time dependent
We then analyzed whether expression of gut homing markers
was vaccine dependent. We found that there was an increase in
Table 1
Baseline characteristics of study participants.
Number 33 13 7 6 4 5 7 6 13 P
Vaccine Vivotif Vivotif Rotarix Rotarix Opvero Opvero Dukoral Dukoral None
ATRA +  +  +  +  +
Age (years) 34 (22–42) 38 (29–40) 21 (19–25) 39 (27–53) 29 (25–33) 20 (19–42) 31 (28–40) 39 (37–40) 28 (22–43) 0.43
HIV Positive (n) 5 2 0 1 1 1 3 4 3
BMI (kg/m2) 20 (19–23) 22 (19–23) 20 (19–21) 20 (19–20) 21 (19–24) 19 (17–25) 20 (18–24) 19 (18–19) 19 (18–24) 0.43
The number of participants randomised to Vivotif includes those in the time course experiments, vaccine comparison experiments and pIgR experiments. Volunteers were all
healthy adult men randomised to receive one or none of the vaccines with or without 10 mg ATRA given daily for 8 days. For vaccine comparisons 8 volunteers were recruited,
pIgR studies had 13 volunteers while the time course studies had 12 volunteers all given Vivotif + ATRA. These are shown as pooled Vivotif vaccine groups. Continuous
variables are shown as median and interquartile range (IQR). ATRA: all-trans retinoic acid, BMI: body mass index.
Fig. 1. Change in specific IgA in intestinal lavage fluid in volunteers given one of three vaccines. ‘Change’ is the difference in log titre values of IgA pre- and 14 days post
vaccination. Antigen-specific IgA responses to Vivotif and Dukoral LPS, Dukoral CTB and Rotarix antigen were measured in whole gut lavage fluid (WGLF). (A) Specific IgA in
WGLF against Vivotif LPS was increased (*P = 0.01) in Vivotif recipients who received ATRA. No change was seen in responses to the other vaccine antigens: (B) Rotarix (P =
0.19), (C) Dukoral LPS (P = 0.83) or (D) Dukoral Cholera Toxin B subunit (CTB) (P = 0.84). Data were analyzed using Mann-Whitney test. Responses are shown measured as
change in log titers.
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and Rotarix groups when compared to those that received only
ATRA. We only observed slightly enhanced CCR9+ CD4+T cells
(Fig. 2C) but not CCR9+CD8+T cells (Fig. 2D) in those given both Viv-
otif and ATRA. When analyzing only activated (HLA-DR+) CD3+ T
cells, it was the CD8+ cells which showed the greatest change in
a4b7 and CCR9 expression (Supplementary Fig. 4). Conversely, a
slight decrease in a4b7+ DR+CD4 +T cells was observed at day 3
(P = 0.02) and day 8 (P = 0.01) in participants that received both
Vivotif and ATRA (Supplementary Fig. 5). These data indicate that
the effect of ATRA is seen only in the presence of antigen and on
day 14 post vaccination.
3.3. ATRA caused a coordinated response of a4b7 integrin and CCR9
only if given simultaneously with Vivotif vaccination
Having established that the co-administration of Vivotif and
ATRA resulted in increased a4b7+CD4+ and CCR9+CD4+ T cells at
day 14, we explored the correlation of these two gut-homingFig. 2. Summary of changes on CD4+ and CD8+T cells expressing a4b7 and CCR9. Volunte
alone. (A) Change in a4b7 expression on CD4+ T cells was significantly higher in particip
Change in a4b7 expression on CD8+ T cells was also significantly higher in the group that
in CCR9 expression on CD4+ T cells was significantly higher in participants that received
ATRA was observed. The changes were calculated by subtracting the pre- vaccination CD
CD4+ T cells. The effects of ATRA were analyzed using the Kruskal-Wallis test.markers. Spearman’s rank test revealed a strong correlation (q =
0.83; P < 0.0001) of these gut homing markers on CD4+T cells
(Fig. 3A), but only when ATRA was given alongside Vivotif. We des-
ignated those individuals with a coordinated increase in these two
gut homing markers as positive responders and those with a coordi-
nated decrease as negative responders. A coordinated increase in
both gut homing markers was observed in 57% (12/21) of volun-
teers that received Vivotif and ATRA simultaneously. This effect
was not seen with Vivotif alone (Fig. 3B), ATRA alone (Fig. 3C) or
Rotarix given with ATRA (Fig. 3D). Our data therefore suggest that
the coordinated gut homing response to ATRA is restricted to the
situation when co-administered with Vivotif.
3.4. Baseline serum retinol was lower in individuals that showed
coordinated responses to a4b7 integrin and CCR9
Baseline serum retinol concentrations (Table 2) in the positive
responders were significantly lower (median of 1.41 mmol/L,
interquartile range 1.06–2.48 mmol/L) than the retinolers received either one of 3 vaccines (Vivotif, Rotarix or Opvero) plus ATRA or ATRA
ants that received Vivotif with ATRA (*P < 0.05) or Rotarix with ATRA (*P = 0.02). (B
received Vivotif with ATRA (*P = 0.03) or Rotarix with ATRA (**P = 0.002). (C) Change
Vivotif with ATRA (*P = 0.02). (D) CCR9 expression on the CD8+ T cells; no effect o
4+ T cells expressing the gut homing markers of interest from the post vaccination)
f
Fig. 3. ATRA induced coordinated expression of a4b7-integrin and CCR9 on CD4+ T cells in Vivotif recipients. (A) Change in a4b7+CD4+ and CCR9+CD4+ was closely
correlated (q = 0.83; P < 0.0001) in participants that received Vivotif with ATRA. Participants given (B) Vivotif alone (q = 0.12; P = 0.83), (C) ATRA alone (q = 0.07; P = 0.82), or
(D) Rotarix with ATRA (q = 0.39; P = 0.38) showed no correlation in gut marker expression respectively. Correlations were analyzed using the Spearman rank correlation test.
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interquartile range 1.68–3.29; P = 0.03). In the positive responder
group, 40% (4/10) of the subjects had serum retinol concentrations
of 1.05 mmol/l, consistent with vitamin A deficiency, compared to
0% (0/7) of negative responders.
3.5. The change in a4b7 on DR+ CD4+ T cells correlated strongly with
the intestinal IgA response to Vivotif
We then looked for a correlation between the change in gut
homing marker expression in blood and the intestinal IgA response
to Vivotif (i.e. gut lavage IgA to Vivotif LPS). The change in a4b7
marker expression on CD4+T cells was strongly correlated withTable 2
Baseline characteristics of positive responders and negative responders.
Characteristic Positive responders Negative responders P
n 12 9
Sex Male Male
Age (mean, years) 36 29
HIV seropositive (n) 3 2
Serum retinol (lmol/L) 1.4 (1.06–2.48) 2.68 (1.68–3.29) 0.03
A retinol concentration of 1 lmol/L was equivalent to 28.the change in specific IgA response to Vivotif LPS in the intestine
in the positive responders only (Fig. 4A). In negative responders
(Fig. 4B), or those given Vivotif alone (Fig. 4C), there was no
correlation.
3.6. Transcriptome analysis
To elucidate the transcriptional changes that occurred during
co-administration of ATRA and the oral vaccine Vivotif, we per-
formed RNA-Seq on blood samples. Transcriptomic changes in
immune-related pathways, particularly including interferon a/b
signaling pathway, membrane-ECM interactions and immune hubs
were observed (Supplementary Table 1). Key immune hubs identi-
fied include fibronectin 1 (FN1), AXL Tyrosine-protein kinase
receptor, complement component 1 (C1QB), complement compo-
nent 4 binding protein (C4BPA) and HLA-DRB1 (Supplementary
Fig. 6).4. Discussion
The global burden of diarrheal disease and the reduced efficacy
of oral vaccines in populations from developing nations have high-
lighted the need for new strategies for vaccination against
Fig. 4. Correlation of change in gut IgA to change in a4b7+DR+CD4+ cells in the positive and negative responders. (A) The positive responders showed a strong correlation (q =
0.82; P = 0.02) of gut IgA to gut marker expression. (B) This was not observed in the negative responders (q = 0.31, P = 0.2) or those given (C) Vivotif alone (q = 0.37; P = 0.2).
Correlations were analyzed using the Spearman rank correlation test.
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has revealed four important effects of ATRA on immune responses
to oral vaccination: First, we have confirmed earlier findings [14]
that ATRA can increase gut mucosal IgA directed at an oral live
attenuated typhoid vaccine, and that this increase is not attributa-
ble to the increased pIgR expression as had been suggested previ-
ously [15]. Secondly, our data suggests that ATRA can increase the
number of circulating CD4+ T cells expressing the gut homing
markers a4b7 and CCR9 in a coordinated and vaccine-specific fash-
ion in a subset of individuals. Thirdly, integrin a4b7 increase was
strongly correlated with the intestinal IgA responses in positive
responders, i.e. those individuals with a coordinated increase in
the gut homing markers. Lastly, we found that ATRA treatment
may cause changes in immune related pathways, including
interferon a/b signaling pathway (adjusted p-value = 0.0015),
membrane-ECM interactions, and immune hubs including fibro-
nectin 1, AXL kinase, complement pathway components and major
histocompatibility complex components such as HLA-DRB1. Since
these elements were impacted by the end of the 8 day ATRA
treatment, we propose that they are responsible, in part, for the
increased responses to Vivotif vaccine.We have demonstrated previously [14] that, in whole gut fluid,
ATRA is able to enhance specific IgA against vaccine antigens sug-
gesting that ATRA could play an adjuvant role when given along-
side Vivotif. To determine whether the adjuvanticity of ATRA
could be translated to other oral vaccines, we evaluated its effect
on three other vaccines; Rotarix, Dukoral and OPVERO vaccines,
all orally administered one hour after administration (or not) of
10 mg ATRA given daily for 8 days. Our data revealed that ATRA
adjuvanticity in this study only occurred with Vivotif and not the
other vaccines, suggesting that the ATRA effect might be vaccine
and/or antigen specific and not a generalizable adjuvant property.
There may be several contributors to the specificity of ATRA in pro-
moting adjuvanticity with Vivotif and not the other oral vaccines.
The most important factor is likely to be the type of immune
responses being elicited by the vaccines. Vivotif induces a vigorous
T-cell response that favours the production of interferon gamma
(IFN-ɣ), tumour necrosis factor-a (TNF-a), interleukin -1 (IL-1)
and IL-6, indicative of a Th1-type response probably through Class
II antigen presentation [31,32]. Rotavirus has been shown to drive
the secretion of TGF-b resulting in inhibition of Th1 responses by
dendritic cells [33]. In one study [34], Rotarix vaccination showed
4140 M. Mwanza-Lisulo et al. / Vaccine 36 (2018) 4134–4141no discernible effect on IFN-ɣ and TNF-a response in a consider-
able proportion [76% (16/21)] of vaccinees. Another study [35]
showed that oral polio vaccine was associated with down regula-
tion of cytokine (IFN-ɣ and TNF-a) production when co-
administered with BCG. The authors speculated that polio virus
might have specific immune modulatory molecules that down-
regulate immune responses to antigens to which immune
responses are being mounted simultaneously. Finally, the inacti-
vated bacterial vaccine Dukoral tends to elicit diminished or
skewed CD4+ T cell responses towards development of a Th2 T cell
phenotype because of the presence of CTB [36]. Of the vaccines
studied, Vivotif was the only vaccine that is likely to elicit a Th1-
type immune response through Class II antigen presentation.
Intriguingly, ATRA led to an increase in several MHC class II com-
ponents including a major component enabling antigen recogni-
tion by T cells, HLADRB1. We hypothesize here that it is the
nature of the context of antigen presentation, in this case for a vac-
cine that generates an IFN-ɣ dominant response, which determines
whether ATRA has an effect [37]. Also, in a pro-inflammatory con-
text involving cytokines, such as IL-15, ATRA probably acts through
dendritic cells to decrease conversion of naïve T cells into T regs
and to enhance Th1 cell polarization. However, this hypothesis will
have to be tested empirically by inclusion of another vaccine group
that elicits a Th1 type response, and that the experimental protocol
would need to include direct demonstration of Th1 and Tregs in
comparison with Th2 and Th17 responses.
To our knowledge, this is only the second study to evaluate
ATRA effects on immune function in humans in vivo, since most
other studies [11,13,38–43] have used in vitro systems or animal
models. Our findings showed an increase in CD4 T cells expressing
a4b7 and CCR9 following oral administration of 10 mg ATRA but
only when given with Vivotif but not Rotarix or OPVERO vaccines.
These results are consistent with other studies in animal models
[11,12,39,40].
There is also evidence that ATRA has effects on other cell types
that also possibly migrate to the gut. Pantazi and colleagues [13]
demonstrated in a murine model, that retinoic acid signaling in B
cells is not essential for their homing to Peyer’s Patches but is nec-
essary in generating antigen-specific IgA responses in the gut.
ATRA has also been found to enhance the migratory properties of
dendritic cells, which is crucial for their antigen presenting func-
tion during infection. We must emphasize that while it would have
been of interest to extend the scope of our work to include B cells,
NK cells and DCs, in a human study one is always constrained by
the experimental procedures which we can conduct, acceptable
volumes of blood to be drawn, and the invasiveness of endoscopic
procedures. Our attention in this study was drawn to T cells
because of the mouse work by other groups [11,41,42] and our
own previous study [14] suggesting that ATRA can augment
responses to Vivotif vaccine.
For safety reasons, one limitation of this study is that it was car-
ried out only in men due to the teratogenicity of ATRA [18,19]; and
with no clear safe dose, ATRA could not be used in women who
might become pregnant during the study. As other studies
[44,45] confirm differences between males and females in
response to vaccination and we suspect that responses in women
would have been different. A further limitation is that we did not
analyse the gut-resident cells to see the effect of ATRA on the gut
immune responses, as we did not have ethical approval to perform
gut lavage and endoscopic biopsies on the same participants.
When the baseline serum retinol concentration was analyzed,
we found that 4/10 (40%) of the positive responders had a clear or
borderline vitamin A deficiency but none of the negative responders
had such deficiency. The difference observed might signify that the
effect of ATRA is seen predominantly in people with borderline
vitamin A deficiency. Also, the data could suggest that the vitaminA deficiency seen in the positive responders may have resulted in
the dendritic cells being altered toward being more inflammatory
producing high levels of IL-13 and TNF-a [46] thus creating a favor-
able environment in which ATRA has an effect. The response to
ATRA and Vivotif was also not explained by HIV infection. A high
proportion of this variability therefore remains unexplained, as
evident from our RNA-Seq studies, so the possibility of an immuno-
genetic predisposition needs to be considered in future work.
It must be pointed out here that ATRA is also obtained from
vitamin A in the diet, and the authors did not control or attempt
to control for diet in the cohort because of the recall bias that doing
a food frequency questionnaire has. It is also apparent from phar-
macological data [14] that oral administration of 10 mg ATRA over
a period of 8 days generates a sharp rise in serum concentrations of
ATRA required to produce the desired immune effects that were
the focus of the current study. Also of note is that ATRA levels were
not monitored longitudinally but only evaluated at two time
points; baseline and day 14 post vaccination.
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